A novel long-acting human growth hormone fusion protein (vrs-317): Enhanced in vivo potency and half-life

Journal of Pharmaceutical Sciences

Volumn 101, Issue 8, 2012, Pages 2744-2754

  Cleland, Jeffrey L ^a   Geething, Nathan C ^b   Moore, Jerome A ^c   Rogers, Brian C ^c   Spink, Benjamin J ^b   Wang, Chai Wei ^b   Alters, Susan E ^b   Stemmer, Willem P C ^b   Schellenberger, Volker ^b  

^a Versartis Inc   (United States)

^b Amunix Inc   (United States)

^c Pacific Biodevelopment   (United States)

Author keywords

Glomerular filtration; Growth hormone; Growth hormone deficiency; Hormones; Long acting; Pharmacodynamics; Pharmacokinetics; Protein delivery; Safety

Indexed keywords

COMPLEMENTARY DNA; EPITOPE; HUMAN GROWTH HORMONE; HYBRID PROTEIN; INTERLEUKIN 3; METHYLPREDNISOLONE; POLYPEPTIDE; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; UNCLASSIFIED DRUG; VRS 317;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BIOPSY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION; GOOD LABORATORY PRACTICE; GROWTH HORMONE DEFICIENCY; HAPLORHINI; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOLOGY; HORMONE RECEPTOR INTERACTION; HYDRODYNAMICS; HYPOPHYSECTOMY; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE; LIPOATROPHY; MALE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RAT; RECEPTOR BINDING; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SWINE; TREATMENT OUTCOME;

EID: 84862890569     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23229     Document Type: Article

References (19)

1. Rosenfeld RG, Bakker B. 2008. Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract 14(2):143-154.
2. Jørgensen JO, Møller N, Lauritzen T, Christiansen JS. 1990. Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: Effects on circulating insulin-like growth factor-I and metabolic indices. J Clin Endocrinol Metab 70(6):1616-1623.
3. Laursen T, Jørgensen JO, Jakobsen G, Hansen BL, Christiansen JS. 1995. Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients. J Clin Endocrinol Metab 80(8):2410-2418.
4. Tauber M, De Bouet Du Portal H, Sallerin-Caute B, Rochiccioli P, Bastide R. 1993. Differential regulation of serum growth hormone (GH)-binding protein during continuous infusion versus daily injection of recombinant human GH in GH-deficient children. J Clin Endocrinol Metab 76(5):1135-1139.
5. Laursen T, Gravholt CH, Heickendorff L, Drustrup J, Kappelgaard AM, Jørgensen JO, Christiansen JS. 2001. Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults. J Clin Endocrinol Metab 86(3):1222-1228.
6. Johnson OL, Cleland JL, Lee HJ, Charnis M, Duenas E, Jaworowicz W, Shepard D, Shahzamani A, Jones AJ, Putney SD. 1996. A month-long effect from a single injection of microencapsulated human growth hormone. Nat Med 2(7):795-799.
7. Kemp SF, Fielder PJ, Attie KM, Blethen SL, Reiter EO, Ford KM, Marian M, Dao LN, Lee HJ, Saenger P. 2004. Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient children. J Clin Endocrinol Metab 89(7):3234-3240.
8. Peter F, Savoy C, Ji HJ, Juhasz M, Bidlingmaier M, Saenger P. 2009. Pharmacokinetic and pharmacodynamic profile of a new sustained-release GH formulation, LB03002, in children with GH deficiency. Eur J Endocrinol 160(3):349-355.
9. Péter F, Bidlingmaier M, Savoy C, Ji HJ, Saenger PH. 2012. Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD). J Clin Endocrinol Metab 97(2):400-407.
10. Biller BM, Ji HJ, Ahn H, Savoy C, Siepl EC, Popovic V, Coculescu M, Roemmler J, Gavrila C, Cook DM, Strasburger CJ. 2011. Effects of once-weekly sustained-release growth hormone: A double-blind, placebo-controlled study in adult growth hormone deficiency. J Clin Endocrinol Metab 96(6):1718-1726.
11. Touraine P, D'Souza GA, Kourides I, Abs R, Barclay P, Xie R, Pico A, Torres-Vela E, Ekman B, GH Lipoatrophy Study Group. 2009. Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH. Eur J Endocrinol 161(4):533-540.
12. de Schepper J, Rasmussen MH, Gucev Z, Eliakim A, Battelino T. 2011. Long-acting pegylated human GH in children with GH deficiency: A single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics. Eur J Endocrinol 165(3):401-409.
13. Reddy GR, Pushpanathan MJ, Ransom RF, Holzman LB, Brosius FC 3rd, Diakonova M, Mathieson P, Saleem MA, List EO, Kopchick JJ, Frank SJ, Menon RK. 2007. Identification of the glomerular podocyte as a target for growth hormone action. Endocrinology 148(5):2045-2055.
14. Roupas P, Herington AC. 1988. Intracellular processing of growth hormone receptors by adipocytes in primary culture. Mol Cell Endocrinol 57(1-2):93-99.
15. Roupas P, Herington AC. 1989. Cellular mechanisms in the processing of growth hormone and its receptor. Mol Cell Endocrinol 61(1):1-12.
16. Johnson V, Maack T. 1977. Renal extraction, filtration, absorption, and catabolism of growth hormone. Am J Physiol 233(3):F185-F196.
17. Schellenberger V, Wang CW, Geething NC, Spink BJ, Campbell A, To W, Scholle MD, Yin Y, Yao Y, Bogin O, Cleland JL, Silverman J, Stemmer WP. 2009. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol 27(12):1186-1190.
18. Rowland JE, Marshall NJ, Leung KC, Ho KK, Cotterill AM, Rowlinson SW, Waters MJ. 2002. A novel bioassay for human somatogenic activity in serum samples supports the clinical reliability of immunoassays. Clin Endocrinol (Oxf) 56(4):475-485.
19. Pearlman R, Bewley TA. 1993. Stability and characterization of human growth hormone. Pharm Biotechnol 5:1-58.